The clinical spectrum of idiopathic inflammatory myopathies (IIMs) has evolved from diseases in which muscle weakness was the main manifestation to systemic inflammatory diseases with multiple organ involvement.
The EULAR–ACR classification criteria for adult and juvenile IIMs and their major subgroups capture patients with the typical skin rash of dermatomyositis without muscle weakness (amyopathic dermatomyositis).
The myositis-specific autoantibodies (MSAs) are helpful in supporting the diagnosis, classification and subclassification of IIMs, but muscle biopsies with histopathological and immunohistochemical evaluation are still important in many cases to rule out other myopathies.
Inclusion body myositis is suggested to be classified on the basis of three features: finger flexor or quadriceps weakness, endomysial inflammation, and invasion of non-necrotic muscle fibres or the presence of rimmed vacuoles.
Immune-mediated necrotizing myopathy is characterized by the presence of necrotic muscle fibres, often with scarce or no inflammatory cell infiltrates, typically together with the presence of specific MSAs.
Antisynthetase syndrome is characterized by the presence of myositis, interstitial lung disease, mechanic's hand, arthritis and Raynaud phenomenon (albeit some of these features might predominate) together with an antisynthetase antibody.
The idiopathic inflammatory myopathies (IIMs; also known as myositis) are a heterogeneous group of disorders in which a common feature is chronic inflammation of skeletal muscle, leading to muscle weakness. Other organs are frequently affected in IIMs, such as the skin, joints, lungs, gastrointestinal tract and heart, contributing to morbidity and mortality. Currently, IIMs are most often subclassified into polymyositis, dermatomyositis and inclusion body myositis, but this subclassification has limitations as these subgroups often have overlapping clinical and histopathological features, and outcomes vary within the subgroups; additionally, subgroups without considerable myopathy are not included. A new way of subgrouping patients could be on the basis of the presence of myositis-specific autoantibodies. These autoantibodies are associated with distinct clinical features and, moreover, can help to identify subsets of IIMs in which extramuscular symptoms, such as skin manifestations, arthritis or interstitial lung disease, might be the presenting or predominant feature when muscle symptoms are mild or absent. The recognition that subphenotypes with single-organ involvement other than muscles exist is important for identifying patients with early disease, for clinical care demanding team management and in designing clinical studies to improve our understanding of this heterogeneous disease to develop new therapies.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dalakas, M. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971–982 (2003).
Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337–345 (2004).
Euwer, R. & Sontheimer, R. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J. Am. Acad. Dermatol. 24, 959 (1991).
Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360–374 (1991).
Lundberg, I. E., Miller, F. W., Tjärnlund, A. & Bottai, M. Diagnosis and classification of idiopathic inflammatory myopathies. J. Intern. Med. 280, 39–51 (2016).
Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 1955–1964 (2017).
Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 69, 2271–2282 (2017).
Medsger, T. A. Jr, Dawson, W. N. Jr & Masi, A. T. The epidemiology of polymyositis. Am. J. Med. 48, 715–723 (1970).
DeVere, R. & Bradley, W. G. Polymyositis: its presentation, morbidity and mortality. Brain 98, 637–666 (1975).
Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344–347 (1975).
Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403–407 (1975).
Bohan, A. & Peter, J. B. Bowman, R. L. & Pearson, C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56, 255–286 (1977).
Tanimoto, K. et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 22, 668–674 (1995).
Targoff, I. N. et al. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9, 527–535 (1997).
Troyanov, Y. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84, 231–249 (2005).
Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J. Rheumatol. 44, 319–325 (2017).
Trallero-Araguás, E. et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin. Arthritis Rheum. 46, 225–231 (2016).
Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8–23 (2016).
McHugh, N.J. & Tansley, S.L. Autoantibodies in myositis Nat. Rev. Rheumatol. https://doi.org/10.1038/nrrheum.2018.56 (2018).
Machado, P. M. et al. Ongoing developments in sporadic inclusion body myositis. Curr. Rheumatol. Rep. 16, 477 (2014).
Pearson, C. M. in Arthritis (and Allied Conditions) (ed. McCarty, D. J.) 742–761 (Lea & Febiger, Philadelphia, 1979).
Euwer, R. & Sontheimer, R. D. Amyopathic dermatomyositis: a review. J. Invest. Dermatol. 100, 124S–127S (1993)
Gerami, P., Schope, J. M., McDonald, L., Walling, H. W. & Sontheimer, R. D. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J. Am. Acad. Dermatol. 54, 597–613 (2006)..
Hsiung, S. H. et al. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. J. Am. Acad. Dermatol. 48 (Suppl. 2). S11–S14 (2003).
Hamaguchi, Y. et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch. Dermatol. 147, 391–398 (2011).
Fiorentino, D., Chung, L., Zwerner, J., Roen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype in dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25–34 (2012).
Muro, Y. et al. Cutaneous manifestations in dermatomyositis: key clinical and serological features — a comprehensive review. Clin. Rev. Allergy Immunol. 51, 293–302 (2016).
Mukae, H. et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136, 1341–1347 (2009).
Ang, C. C. et al. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. Br. J. Dermatol. 176, 231–233 (2017).
Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449–455 (2015).
Fiorentino, D. & Casciola-Rosen, L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 64, 346–349 (2012).
Rogers, A., Chung, L., Li. S., Casciola-Rosen, L. & Fiorentino, D. F. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909–1914 (2017).
Fujimoto, M., Watanabe, R., Ishitsuka, Y. & Okiyama, N. Recent advances in dermatomyositis-specific autoantibodies. Curr. Opin. Rheumatol. 28, 636–644 (2016).
Klein, R. Q. et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br. J. Dermatol. 159, 887–894 (2008).
Anyanwu, C. O. et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br. J. Dermatol. 173, 969–974 (2015).
Tiao, J. et al. Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 177, 1086–1092 (2017).
Tiao, J. et al. The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 176, 423–430 (2017).
Robinson, E. S., Feng, R., Okawa, J. & Werth, V. P. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br. J. Dermatol. 172, 169–174 (2015).
Yassaee, M., et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br. J. Dermatol. 162, 669–673 (2010).
Goreshi, R. et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J. Invest. Dermatol. 132, 1117–1124 (2012).
Huard, C. et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br. J. Dermatol. 176, 1224–1230 (2017).
Werth, V. P. et al. A phase 2 study of safety and efficacy o anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis [abstract]. Arthritis Rheum. 69 (Suppl.), 7L (2017).
Engel, A. G. &Arahata, K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann. Neurol. 16, 209–215 (1984).
Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343–356 (1990).
Griggs, R. C., et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705–713 (1995).
Van der Meulen, M. F. et al. Polymyositis: an overdiagnosed entity. Neurology 12, 316–321 (2003).
Brady, S., Squier, W. & Hilton-Jones, D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J. Neurol. Neurosurg. Psychiatr. 84, 1240–1246 (2013).
Rose, M. R. & ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044–1055 (2013).
Lloyd, T. E. et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 29, 426–433 (2014).
Stenzel, W., Goebel, H. H. & Aronica, E. Review: immunemediated necrotizing myopathies– a heterogeneous group of diseases with specific myopathological features. Appl. Neurobiol. Neuropathol. 38, 632–646 (2012).
Allenbach, Y. et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul. Disord. 28, 87–99 (2018).
Van de Vlekkert, J., Hoogendijk, J. E. & de Visser, M. Long-term follow-up of 62 patients with myositis. J. Neurol. 261, 992–998 (2014).
Pinal-Fernandez, I., Casciola-Rosen, L. A., Christopher-Stine, L., Corse, A. M. & Mammen, A. L. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J. Rheumatol. 42, 1448–1454 (2015).
Allenbach, Y., Benveniste, O., Goebel, H.-H. & Stenzel, W. Integrated classification of inflammatory myopathies. Neuropathol. Appl. Neurobiol. 43, 62–81 (2017).
Noguchi, E. et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 74, 992–999 (2017).
Mozaffar, T. & Pestronk, A. Myopathy with anti-Jo-1 antibodies: Pathology in perimysium and neighbouring muscle fibres. J. Neurol. Neurosurg. Psychiatry, 68, 472–478 (2000).
Aouizerate, J. et al. Myofiber HLA-DR espression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol. Commun. 23, 154 (2014).
Mescam-Mancini, L. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138, 2485–2492 (2015).
Stenzel, W. et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome–induced dysimmune myopathy. Neurology 84, 1346–1354 (2015).
Uruha, A., Suzuki, S., Suzuki, N. & Nishino, I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain 139, e50 (2016).
Pinal-Fernandez, I. & Mammen, A. L. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr. Opin. Rheumatol. 28, 619–624 (2016).
De Visser, M., Emslie-Smith, A. M. & Engel, A. G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J. Neurol. Sci. 94, 181–192 (1989).
Wedderburn, L. R. et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 57, 1192–1201 (2007).
Patel, B. Neelam, K. & Werth, V. P. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2017.12.055 (2017).
Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487–1498 (1991).
Pestronk, A. Acquired immune and inflammatory myopathies: pathologic classification. Curr. Opin. Rheumatol. 23, 595–604 (2011).
The authors thank A. Tjärnlund for being the research coordinator of the International Myositis Classification Criteria Project (IMCCP) and for the critical reading of this manuscript. The authors also thank the IMCCP consortium. The authors thank V. Leclair for her help with Fig. 1. V.P.W. was involved in the development of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI); the copyright for this instrument is owned by the University of Pennsylvania. This work was supported by the US NIH (R21 AR066286 and K24-AR 02207) as well as a US Veterans Affairs Merit Review grant (I01BX000706) (V.P.W.). I.E.L. has received grant support from the Swedish Research Council and the Regional Agreement on Medical Training and Clinical Research between the Stockholm County Council and Karolinska Institutet.
The authors declare no competing financial interests.
A pink, red or purplish colouring around the eyes and eyelids, with or without oedema.
- Gottron sign
A symmetrical, occasionally scaly, erythematous eruption over the extensor surfaces of the metacarpophalangeal and interphalangeal joints of the fingers, knees and elbows.
- Gottron papules
Red, and often scaly, papules overlying the extensor surfaces of the metacarpophalangeal and interphalangeal joints of the fingers.
Areas of hypopigmentation, hyperpigmentation, telangiectasias and atrophy of the skin.
Dilated capillaries that can be seen in areas of poikiloderma or at the proximal nailfold.
- Interface dermatitis
Dermatitis in which the primary pathology involves the dermo-epidermal junction, with basal cell vacuolization, apoptotic keratinocytes and a band-like infiltrate of inflammatory cells at the dermo-epidermal junction; other characteristics in dermatomyositis include lymphocytic perivascular infiltrates and interstitial mucin deposition.
- Mechanic's hand
The presence of scaling, fissuring, hyperpigmentation and hyperkeratosis, distributed in a characteristic fashion on the lateral fingers and sometimes the palmar surfaces, fingertips and distal skin, as well on the feet.
- Palmar hyperkeratotic papules
Describes scaly verrucous papules on the palm.
About this article
Cite this article
Lundberg, I., de Visser, M. & Werth, V. Classification of myositis. Nat Rev Rheumatol 14, 269–278 (2018). https://doi.org/10.1038/nrrheum.2018.41
Cellular & Molecular Immunology (2021)
Nature Reviews Rheumatology (2021)
Giant cell myositis associated with concurrent myasthenia gravis: a case-based review of the literature
Clinical Rheumatology (2021)
The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease
Neurological Sciences (2021)
Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
Clinical Rheumatology (2021)